Skip to content

Study · Randomized controlled trial · n = 38 · 2020

8 results

Loading modality and age influence teriparatide-induced bone formation in the human femoral neck.

Rooney AM, Bostrom MPG, Dempster DW, Nieves JW, Zhou H, Cosman F

Bone21 Apr 2020Cited by 8 (Europe PMC)

PMID32330694 (opens in a new tab)PMCIDPMC7263665 (opens in a new tab)DOI10.1016/j.bone.2020.115373 (opens in a new tab)PepBankPUB-32330694
Source linkPubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients undergoing hip replacement for osteoarthritis, teriparatide increased endocortical bone formation compared with placebo.

    In plain wordsIn patients undergoing hip replacement, teriparatide increased bone formation on the inner cortical surface compared with placebo.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseEndocortical bone formation
    Study

    n = 38

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · mean 6 weeksAs given in this study (human).

    Source sentences

    Summary
    Overall, bone formation was higher with TPTD versus placebo on the endocortical surface, but not the periosteal surface.
    2 context sentences
    Summary · context
    Thirty-eight patients receiving total hip replacements for osteoarthritis were randomized to receive placebo (PBO) or TPTD for a mean treatment duration of 6 weeks prior to surgery, and double tetracycline labeling was administered to allow assessment of bone formation.
    Summary · context
    The FN was harvested during surgery and analyzed for dynamic bone formation indices in the compressive and tensile regions of the endocortical and periosteal envelopes.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In patients undergoing hip replacement for osteoarthritis, teriparatide did not increase periosteal bone formation compared with placebo.

    In plain wordsIn patients undergoing hip replacement, teriparatide did not increase bone formation on the outer surface compared with placebo.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changePeriosteal bone formation
    Study

    n = 38

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · mean 6 weeksAs given in this study (human).

    Source sentences

    Summary
    Overall, bone formation was higher with TPTD versus placebo on the endocortical surface, but not the periosteal surface.
    2 context sentences
    Summary · context
    Thirty-eight patients receiving total hip replacements for osteoarthritis were randomized to receive placebo (PBO) or TPTD for a mean treatment duration of 6 weeks prior to surgery, and double tetracycline labeling was administered to allow assessment of bone formation.
    Summary · context
    The FN was harvested during surgery and analyzed for dynamic bone formation indices in the compressive and tensile regions of the endocortical and periosteal envelopes.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In patients undergoing hip replacement, teriparatide showed a trend toward decreased compressive endocortical eroded surface compared with placebo.

    In plain wordsIn patients undergoing hip replacement, teriparatide showed a trend toward less inner-surface erosion in the compressive region compared with placebo.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseCompressive endocortical eroded surface
    Study

    n = 38

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · mean 6 weeksAs given in this study (human).

    Source sentences

    Summary
    There was a trend toward decreased endocortical eroded surface with TPTD in the compressive but not the tensile region.
    2 context sentences
    Summary · context
    Thirty-eight patients receiving total hip replacements for osteoarthritis were randomized to receive placebo (PBO) or TPTD for a mean treatment duration of 6 weeks prior to surgery, and double tetracycline labeling was administered to allow assessment of bone formation.
    Summary · context
    The FN was harvested during surgery and analyzed for dynamic bone formation indices in the compressive and tensile regions of the endocortical and periosteal envelopes.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In patients undergoing hip replacement, teriparatide showed no trend toward decreased tensile endocortical eroded surface compared with placebo.

    In plain wordsIn patients undergoing hip replacement, teriparatide showed no trend toward less inner-surface erosion in the tensile region compared with placebo.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeTensile endocortical eroded surface
    Study

    n = 38

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · mean 6 weeksAs given in this study (human).

    Source sentences

    Summary
    There was a trend toward decreased endocortical eroded surface with TPTD in the compressive but not the tensile region.
    2 context sentences
    Summary · context
    Thirty-eight patients receiving total hip replacements for osteoarthritis were randomized to receive placebo (PBO) or TPTD for a mean treatment duration of 6 weeks prior to surgery, and double tetracycline labeling was administered to allow assessment of bone formation.
    Summary · context
    The FN was harvested during surgery and analyzed for dynamic bone formation indices in the compressive and tensile regions of the endocortical and periosteal envelopes.

Studies that did not test the peptide alone4

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

  1. 05HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome

    In hip replacement samples, endocortical bone formation was greater on the tensile surface in both teriparatide and placebo groups.

    In plain wordsIn hip samples, both teriparatide and placebo groups showed greater inner-surface bone formation in tensile regions.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseEndocortical bone formation by loading region
    Study

    n = 38

    Comparator
    Compressive endocortical surface
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    The level of bone formation in both TPTD and placebo groups was greater on the tensile endocortical surface and the compressive periosteal surface.
    2 context sentences
    Summary · context
    Thirty-eight patients receiving total hip replacements for osteoarthritis were randomized to receive placebo (PBO) or TPTD for a mean treatment duration of 6 weeks prior to surgery, and double tetracycline labeling was administered to allow assessment of bone formation.
    Summary · context
    The FN was harvested during surgery and analyzed for dynamic bone formation indices in the compressive and tensile regions of the endocortical and periosteal envelopes.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  2. 06HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyOther

    In hip replacement patients studied with teriparatide or placebo, age and sex explained the greatest variability in endocortical bone formation.

    In plain wordsIn hip replacement patients studied with teriparatide or placebo, age and sex explained the greatest variation in inner-surface bone formation.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    Not applicablePatient predictors of endocortical bone formation
    Study

    n = 38

    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    Patient age and sex explained the greatest variability in endocortical bone formation
    2 context sentences
    Summary · context
    Thirty-eight patients receiving total hip replacements for osteoarthritis were randomized to receive placebo (PBO) or TPTD for a mean treatment duration of 6 weeks prior to surgery, and double tetracycline labeling was administered to allow assessment of bone formation.
    Summary · context
    The FN was harvested during surgery and analyzed for dynamic bone formation indices in the compressive and tensile regions of the endocortical and periosteal envelopes.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  3. 07HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyOther

    In hip replacement patients studied with teriparatide or placebo, body mass and sex explained the greatest variability in periosteal bone formation.

    In plain wordsIn hip replacement patients studied with teriparatide or placebo, body mass and sex explained the greatest variation in outer-surface bone formation.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    Not applicablePatient predictors of periosteal bone formation
    Study

    n = 38

    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    and patient body mass and sex explained the greatest variability in periosteal bone formation.
    2 context sentences
    Summary · context
    Thirty-eight patients receiving total hip replacements for osteoarthritis were randomized to receive placebo (PBO) or TPTD for a mean treatment duration of 6 weeks prior to surgery, and double tetracycline labeling was administered to allow assessment of bone formation.
    Summary · context
    The FN was harvested during surgery and analyzed for dynamic bone formation indices in the compressive and tensile regions of the endocortical and periosteal envelopes.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  4. 08HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome

    In hip replacement samples, periosteal bone formation was greater on the compressive surface in both teriparatide and placebo groups.

    In plain wordsIn hip samples, both teriparatide and placebo groups showed greater outer-surface bone formation in compressive regions.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreasePeriosteal bone formation by loading region
    Study

    n = 38

    Comparator
    Tensile periosteal surface
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    The level of bone formation in both TPTD and placebo groups was greater on the tensile endocortical surface and the compressive periosteal surface.
    2 context sentences
    Summary · context
    Thirty-eight patients receiving total hip replacements for osteoarthritis were randomized to receive placebo (PBO) or TPTD for a mean treatment duration of 6 weeks prior to surgery, and double tetracycline labeling was administered to allow assessment of bone formation.
    Summary · context
    The FN was harvested during surgery and analyzed for dynamic bone formation indices in the compressive and tensile regions of the endocortical and periosteal envelopes.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.